GlobeNewswire

Z-Wave Alliance Brings Diverse Smart Home Ecosystem to International Integrators at ISE 2018

Del

The Z-Wave Pavilion will feature the latest smart home devices for the pro channel from member companies along with the now available global Z-Wave toolkit for Z-Wave projects

 

AMSTERDAM, the Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ISE 2018 -- Stand 9-F170  -- The Z-Wave Alliance, a global membership organization dedicated to advancing the popular Z-Wave wireless smart home protocol, will host the Z-Wave Pavilion at ISE 2018. The Alliance is also demoing their award-winning installation toolkit to make installation and testing of a Z-Wave smart home mesh network even easier for the pro installer community.

The Z-Wave Pavilion will feature smart home products & services for integrators such as new smart door locks for residential and MDU applications, smart entertainment control, advanced IoT sensors and more at ISE 2018. Featured members in the Pavilion include:

  • Aeotec
  • ASSA ABLOY
  • eZLO
  • Fifthplay
  • Hogar Controls
  • LEEDARSON
  • Neeo
  • Oblo Living
  • UTC

"The smart home market is on the move in the UK and Europe and so are our European-based members; we've got a host of new products and solutions being shown off at ISE specifically for the integrator community," said Mitchell Klein, Z-Wave Alliance Executive Director. "Our Certified Installer Toolkit is now available to integrators around the globe and we were excited to take home several Best of awards at CEDIA this year. It truly is an invaluable tool for the installation community."

Z-Wave will also show off the award-winning Z-Wave Certified Installer Toolkit (CIT), available now for integrators around the world to assist in setting up and maintaining Z-Wave networks in their installation projects. The Z-Wave CIT is the only integrator diagnostics device to include global language support.

Integrators who purchase a toolkit at ISE 2018 will receive their first-year of Z-Wave Alliance membership for only one dollar. After purchase of a CIT, all software updates and upgrades will be available at no charge if the integrator remains a member in good standing. Additional toolkits will be available for purchase for all Alliance members. For more information on the CIT, visit the website.

For more information on the Z-Wave Alliance, please visit http://z-wavealliance.org. For updates from Z-Wave at ISE 2018,  follow the Z-Wave Alliance on FacebookTwitter and LinkedIn and with the #ISE2018 hashtag.

About Z-Wave
Z-Wave® technology is an open internationally recognized ITU standard (G.9959). It is the leading wireless home control technology in the market today, with over 2400 certified interoperable products worldwide.  Represented by the Z-Wave Alliance, and supported by more than 700 companies around the world, the standard is a key enabler of smart living solutions for home safety and security, energy, hospitality, office and light commercial applications.

Z-Wave® is a registered trademark of Sigma Designs (NASDAQ SIGM) and its subsidiaries in the United States and other countries.

About the Z-Wave Alliance
Formed in January 2005, the Z-Wave Alliance is a consortium of leading companies in the home technology space dedicated to solidifying Z-Wave as the standard for wireless home control products. The principal members include: ADT, Alarm.com, ASSA ABLOY, FIBARO, Huawei, Ingersoll Rand Nexia Intelligence, Jasco Products, Leedarson, LG Uplus, Nortek Security & Control, SmartThings and Sigma Designs.  Alliance members lead the home controls market, providing leading edge products and systems that deliver increased comfort, convenience, energy conservation, safety and security.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements about the benefits of Z-Wave Alliance membership, the benefits of the use of Z-Wave in product offerings, including the benefits of certain enhanced features of Z-Wave devices. Actual results may vary materially due to a number of factors including, but not limited to, consumer and customer acceptance of the Z-Wave Alliance (including its membership benefits), and Z-Wave technology in the relevant regions, the ability of the Z-Wave Alliance to compete with similar alliances in the industry and of the Z-Wave technology to compete with other technologies or related products in the market, if any, as well as other risks that are detailed from time to time in Z-Wave Alliance Members' reports to the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. We undertake no obligation to publically release or otherwise disclose the result of any revision to these forward-looking statements that may be made as a result of events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Press Contact:  
Caster Communications, Inc. at 401.792.7080
Ashley Daigneault ashley@castercomm.com (401) 651-3242
Alexandra Gil alex@castercomm.com (401) 792-7080

For digital images log on to www.castercomm.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Z-Wave Alliance via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

WillScot to Participate at the Barclays Industrial Select Conference16.1.2019 21:00Pressemelding

BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”)(NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Barclays Industrial Select Conference at the Loews Miami Beach Hotel in Miami, Florida, on Wednesday, Feb. 20, 2019. The presentation will take place at 10:20 a.m. EST. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the WillScot family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for t

CCI has been retained by Waterloo Brewing to obtain Cannabis Licence16.1.2019 16:00Pressemelding

TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce they have partnered with Waterloo Brewing to help them obtain their Research and standard Processing Licence to develop cannabis-infused beverages. “CCI is working with Waterloo Brewing on the early stages of the application process and we are confident that we will help them achieve their desired licenses in time to be an active player in this growing sector of the cannabis industry”, said Brian Wagner, CEO and Founder, Cannabis Compliance Inc. “We are here to guide our clients through the early stages of the licensing process and for the many Health Canada requirements thereafter.” CCI offers end to end business solutions for cannabis companies large and small. Our team brings with them years of experience in the quality, regulatory, security and cultivation sectors, and supports manufacturers and retailers through regulatory challenges. As the world’s largest and mos

Aryaka Announces Expansion of Senior Leadership Team with New Chief Revenue Officer, Chief Transformation Officer and Chief Marketing Officer16.1.2019 15:00Pressemelding

Karen Freitag, Michelle Owczarzak, & Shashi Kiran join Aryaka to address significant growth and assist global enterprises in adopting managed connectivity as-a-service SAN MATEO, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aryaka®, announced today the appointment of several new executive hires to the company’s leadership team, including Karen Freitag (Chief Revenue Officer), Michelle Owczarzak (Chief Transformation Officer), and Shashi Kiran (Chief Marketing Officer). “Connectivity is the lifeblood of the global enterprise and Aryaka is the industry benchmark for secure managed connectivity worldwide. We are excited to have experienced industry veterans join our robust executive leadership team and continue to help build upon the immense success and growth that Aryaka has seen in recent years,” said Matt Carter, CEO of Aryaka. “As our customers expand globally, embrace SD-WAN, or move to the cloud, we’re becoming the de facto choice for their needs to make this happen better, faster, che

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors16.1.2019 07:00Pressemelding

Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic. ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated

GSA Europe’s Managing Director Elected Co-lead of CEN’s TC456 Committee15.1.2019 21:12Pressemelding

SAN GWANN, Malta, Jan. 15, 2019 (GLOBE NEWSWIRE) -- GSA Europe’s Managing Director Mark Pace has been elected by the Comité Européen de Normalisation (CEN) to lead the creation of a European Union online gaming reporting standard. CEN has established Technical Committee 456 to create this standard in support of online gambling supervision. GSA Europe joined Technical Committee 456 as a Liaison Organization in 2017. The Technical Committee’s mandate from the European Commission is directly aligned with work that GSA Europe has already started, namely, to create a single standard set of data elements and single standard way in which data is provided by online gambling providers to EU Member State regulatory authorities. In addition to joining and now leading the Technical Committee’s work, GSA Europe also donated their draft Regulatory Data Set and Regulatory Reporting Interface to CEN seeking to help jump-start the Committee’s work. “Joining CEN’s TC456 as a Liaison Organization, and no

Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study15.1.2019 15:00Pressemelding

OTTAWA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started with OB-002O, a murine anti-PD-1 antibody, OB-002 + anti-PD-1, or saline placebo. Treatment was given daily or every third day. Treatment with OB-0020 alone led to statistically significant delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed in combination cohort where animals received both, OB-0020 and the anti-PD-1 antibody (p>0.05). “There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist